Recombinant Human Interleukin-1 Receptor Antagonist Provides Cardioprotection During Myocardial Ischemia Reperfusion in the Mouse |
| |
Authors: | Stefano Toldo Aaron M. Schatz Eleonora Mezzaroma Raveen Chawla Thomas W. Stallard William C. Stallard Arehzo Jahangiri Benjamin W. Van Tassell Antonio Abbate |
| |
Affiliation: | VCU Pauley Heart Center, Virginia Commonwealth University, 1200 E. Broad St. 10th floor, Richmond, VA 23298, USA. stoldo2@vcu.edu |
| |
Abstract: | Purpose Acute myocardial infarction (AMI) drives an intense inflammatory response that contributes to infarct healing and cardiac remodeling. Recently, different studies have identified a role of interleukin-1 (IL-1) in the development of adverse cardiac remodeling. However, in animal models of AMI IL-1 has been shown to be cardioprotective in preconditioning, raising the question of clinical safety of therapeutic IL-1 blockade for autoinflammatory diseases or for the prevention or the treatment of AMI. In this study we proposed to evaluate the effects of pretreatment with recombinant human interleukin-1 receptor antagonist (rhIL-1Ra) on ischemia reperfusion (I/R) injury to the heart. Methods RhIL-1Ra was given 4?h or 30?min before the surgical induction of I/R. Left ventricular ejection fraction(LVEF) and infarct size were assessed to determine the effects of the drug pretreatment compared to vehicle treated mice. Results RhIL-1Ra, given 4?h or 30?min before the onset of the ischemia, showed marked cardioprotection though preservation of the LVEF (no change vs sham operated mice) and the reduction of the infarct size (?40?% vs vehicle-treated mice). No differences were observed between the two groups of rhIL-1Ra treatment. Conclusions IL-1 blockade therapies using rhIL-1Ra prior the onset of AMI protects the myocardium and preserves cardiac function. |
| |
Keywords: | |
本文献已被 PubMed SpringerLink 等数据库收录! |
|